title: Advanced nasopharyngeal carcinoma treated with chemotherapy and radiotherapy: distant metastasis and local recurrence.
abstract: One hundred and twenty-nine patients with NPC treated at the Department of Radiology, Chiba University Hospital and Keio University Hospital from 1980 through 1993 were selected for this study. Forty-four patients received cisplatin (CDDP)- or carboplatin-based chemotherapy, and 58 patients received adriamycin (ADM)- and/or 5-FU-based chemotherapy. The remaining 27 patients were treated with radiotherapy alone. The median radiation dose to the nasopharyngeal region was 64 Gy, and to the initially involved cervical node, 60 Gy. The 5 year survival rates for the CDDP, the ADM/5-FU and the radiation alone groups were 61%, 47% and 42%, respectively. The cumulative incidences of local control in the CDDP, the ADM/5-FU and the radiation alone groups were 77%, 49% and 53% respectively. The CDDP group achieved the significantly better local control (CDDP vs ADM: p=0.001). The overall incidence of distant metastases was 54% in the CDDP group. On the other hand, it was 24% in the ADM/5-FU group and 22% in the radiation alone group (CDDP vs ADM: p=0.048). While the locoregional control rate was significantly better in the CDDP given group, more distant metastases were seen in this group.
authors.affiliation: Department of Radiology, Chiba University, School of Medicine, 1-8-1 Inohana, Chuoku, Chiba city 260, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Isobe
authors.forename: H
authors.initials: H
authors.lastname: Ito
authors.forename: N
authors.initials: N
authors.lastname: Shigematsu
authors.forename: T
authors.initials: T
authors.lastname: Kawada
authors.forename: S
authors.initials: S
authors.lastname: Yasuda
authors.forename: R
authors.initials: R
authors.lastname: Hara
authors.forename: N
authors.initials: N
authors.lastname: Machida
authors.forename: H
authors.initials: H
authors.lastname: Takano
authors.forename: Y
authors.initials: Y
authors.lastname: Uchida
authors.forename: T
authors.initials: T
authors.lastname: Uno
authors.forename: H
authors.initials: H
authors.lastname: Kitahara
authors.forename: A
authors.initials: A
authors.lastname: Kubo
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D012008:Recurrence; D015996:Survival Rate; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D004317:Doxorubicin; D016190:Carboplatin; D002945:Cisplatin; D005472:Fluorouracil